Advanced Oncotherapy PLC Director Dealing (3826C)
13 April 2017 - 4:00PM
UK Regulatory
TIDMAVO
RNS Number : 3826C
Advanced Oncotherapy PLC
13 April 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that yesterday, Dr Enrico Vanni purchased 100,000
Ordinary Shares of 25 pence in the Company ("Ordinary Shares") at a
price of 27.5 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 1,023,946
Ordinary Shares, representing 1.40% of the issued share capital of
73,016,500 Ordinary Shares as at 12 April 2017.
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Tel: +44 20 3617 8728
Executive Chairman
Nicolas Serandour, CEO
Stockdale Securities (Nomad
& Joint Broker)
Antonio Bossi / David Tel: +44 20 7601 6100
Coaten
Stifel Nicolaus Europe
(Joint Broker)
Jonathan Senior / Ben Tel: +44 20 7710 7600
Maddison
Walbrook PR (Financial Tel: +44 20 7933 8780 or
PR & IR) avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 /
Mob: +44 7876 741 001
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced
Oncotherapy's team "ADAM", based in Geneva, focuses on the
development of a proprietary proton accelerator called Linac Image
Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the
energy levels achieved in legacy machines but in a unit that is a
quarter of the size and between a quarter and a fifth of the cost.
This compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control which is not
achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBLGDSGSBBGRD
(END) Dow Jones Newswires
April 13, 2017 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024